Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 7/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.35 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.33 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20465386 | 0.95 | AAK1 (0.46) | AAK1TRPA1GABRB1GABRB2GRM2 | |
| SCHEMBL20054545 | 0.84 | AAK1 (0.64) | AAK1TRPV1SCN10ASCN9ALCK | |
| SCHEMBL15116826 | 0.84 | AAK1 (0.64) | AAK1TRPV1SCN10ASCN9ALCK | |
| SCHEMBL20465384 | 0.83 | AAK1 (0.42) | AAK1TRPA1GABRB1GABRB2SCN10A | |
| SCHEMBL20468381 | 0.81 | AAK1 (0.38) | AAK1SCN10APRCP | |
| SCHEMBL21894503 | 0.81 | AAK1 (0.38) | AAK1SCN10APRCP | |
| SCHEMBL18482392 | 0.81 | AAK1 (0.38) | AAK1SCN10APRCP | |
| SCHEMBL20468286 | 0.81 | AAK1 (0.38) | AAK1SCN10APRCP | |
| SCHEMBL16532762 | 0.78 | AAK1 (0.50) | AAK1LCK | |
| SCHEMBL15116746 | 0.78 | AAK1 (0.50) | AAK1SCN10ALCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10617675-B2 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-04-14 | — | — | US | disclosed |
| US-20180221342-A1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10617675-B2 | Hepatitis C virus inhibitors | HAVCR2, MAVS, EIF2AK2 | AAK1 2213/4885TRPA1 4722/4885GABRB1 3608/4885 |
| US-20180221342-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, MAVS, EIF2AK2 | AAK1 2213/4885TRPA1 4722/4885GABRB1 3608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.